Decoding the Neural Code,
Restoring the Dignity of Life
BioLumina Pty Ltd develops next-generation minimally invasive implantable BCI devices, enabling severely paralyzed patients to regain the ability to communicate and live autonomously.
Our Approach
We have pioneered a cross-border model of "Australian Technology + Chinese Intelligent Manufacturing + Global Market."
Endovascular BCI
No craniotomy required. Our NeuralStent™ is delivered via the jugular vein to the motor cortex, dramatically reducing surgical risk.
TGA Regulatory Path
Leveraging Australia's rigorous TGA Priority Review pathway to build international credibility and reach global markets.
Asia-Pacific Market
Simultaneously accelerating NMPA approval via the Boao Lecheng Real-World Data Study program to access China's vast market.
Target Indications
Addressing severe neurological conditions where patients lose the ability to communicate or move.
ALS (Late Stage)
Mind-typing and device control for patients with amyotrophic lateral sclerosis.
Severe SCI
Restoring communication for patients with severe spinal cord injury or locked-in syndrome.
Severe Aphasia
Future expansion to assist communication for patients with severe aphasia.
Interested in Partnering?
We welcome collaborations with hospitals, research institutions, and investors who share our vision.
Contact Us